| Literature DB >> 24034499 |
Matthew A Nakatsuka1, Christopher V Barback, Kirsten R Fitch, Alexander R Farwell, Sadik C Esener, Robert F Mattrey, Jennifer N Cha, Andrew P Goodwin.
Abstract
The use of microbubbles as ultrasound contrast agents is one of the primary methods to diagnose deep venous thrombosis. However, current microbubble imaging strategies require either a clot sufficiently large to produce a circulation filling defect or a clot with sufficient vascularization to allow for targeted accumulation of contrast agents. Previously, we reported the design of a microbubble formulation that modulated its ability to generate ultrasound contrast from interaction with thrombin through incorporation of aptamer-containing DNA crosslinks in the encapsulating shell, enabling the measurement of a local chemical environment by changes in acoustic activity. However, this contrast agent lacked sufficient stability and lifetime in blood to be used as a diagnostic tool. Here we describe a PEG-stabilized, thrombin-activated microbubble (PSTA-MB) with sufficient stability to be used in vivo in circulation with no change in biomarker sensitivity. In the presence of actively clotting blood, PSTA-MBs showed a 5-fold increase in acoustic activity. Specificity for the presence of thrombin and stability under constant shear flow were demonstrated in a home-built in vitro model. Finally, PSTA-MBs were able to detect the presence of an active clot within the vena cava of a rabbit sufficiently small as to not be visible by current non-specific contrast agents. By activating in non-occlusive environments, these contrast agents will be able to detect clots not diagnosable by current contrast agents.Entities:
Keywords: Clotting; DNA; In vitro test; In vivo test; Thrombosis
Mesh:
Substances:
Year: 2013 PMID: 24034499 PMCID: PMC3788116 DOI: 10.1016/j.biomaterials.2013.08.040
Source DB: PubMed Journal: Biomaterials ISSN: 0142-9612 Impact factor: 12.479